Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/25/2020 11/26/2020 11/27/2020 11/30/2020 12/01/2020 Date
82.9(c) 83.5(c) 85(c) 85.9(c) 84.5(c) Last
6 543 6 196 8 427 19 440 11 314 Volume
-0.72% +0.72% +1.80% +1.06% -1.63% Change
More quotes
Financials
Sales 2020 53,1 M 64,0 M 64,0 M
Net income 2020 -8,53 M -10,3 M -10,3 M
Net cash position 2020 51,0 M 61,4 M 61,4 M
P/E ratio 2020 -144x
Yield 2020 -
Sales 2021 64,8 M 78,1 M 78,1 M
Net income 2021 -9,95 M -12,0 M -12,0 M
Net cash position 2021 39,0 M 47,0 M 47,0 M
P/E ratio 2021 -130x
Yield 2021 -
Capitalization 1 222 M 1 349 M 1 472 M
EV / Sales 2020 22,0x
EV / Sales 2021 18,2x
Nbr of Employees 261
Free-Float 45,8%
More Financials
Company
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline... 
More about the company
Notations Surperformance© of Cosmo Pharmaceuticals N.V.
Trading Rating : Investor Rating :
More Ratings
All news about COSMO PHARMACEUTICALS N.V.
01:05aCosmo Pharmaceuticals appoints new Chief Medical Officer
TE
01:05aCosmo Pharmaceuticals ernennt neuen Chief Medical Officer
TE
11/24COSMO PHARMACEUTICALS N : Announces Senior Leadership Changes
AQ
11/23Cosmo Pharmaceuticals Announces Senior Leadership Changes
TE
11/23Cosmo Pharmaceuticals kündigt Wechsel im Führungsteam an
TE
11/20COSMO PHARMACEUTICALS N : announces expansion of agreement with Dr. Falk Pharma ..
AQ
11/19Cosmo Pharmaceuticals announces expansion of agreement with Dr. Falk Pharma f..
TE
11/18COSMO PHARMACEUTICALS N : announces approval of Eleview in Japan
AQ
11/17Cosmo Pharmaceuticals announces approval of Eleview® in Japan
TE
10/12COSMO PHARMACEUTICALS N : Acacia Pharma completes drawdown from EUR25 million lo..
AQ
08/28COSMO PHARMACEUTICALS N : announces FDA Approval for Cassiopea's Winlevi, First-..
AQ
08/27Cassiopea gets U.S. FDA approval for acne treatment Winlevi
RE
08/27COSMO PHARMACEUTICALS N : announces FDA Approval for Cassiopea's Winlevi ® (clas..
PU
08/27Cosmo Pharmaceuticals announces FDA Approval for Cassiopea's Winlevi® (clasco..
TE
08/24COSMO PHARMACEUTICALS N : NV - Methylene Blue MMX approved in Europe for the vis..
AQ
More news
News in other languages on COSMO PHARMACEUTICALS N.V.
02:00aCosmo ernennt Jurgen Lenz zum neuen medizinischen Leiter
01:56aCosmo désigne Jurgen Lenz comme directeur médical
11/23Cosmo-COO Giuseppe Cipriano wechselt Funktion und wird Chief People Officer
11/23Cosmo procède à deux changements à sa direction générale
11/19Bourse Zurich: clôture en baisse, la peur de la crise reprend ses quartiers
More news
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 102,69 €
Last Close Price 84,50 €
Spread / Highest target 31,7%
Spread / Average Target 21,5%
Spread / Lowest Target 11,6%
EPS Revisions
Managers
NameTitle
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Executive Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Davide Malavasi Director-Qualified Person & Technical
Sector and Competitors
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.11.99%1 371
JOHNSON & JOHNSON-0.82%380 876
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389